An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies
Stopped As of 31 JAN 2018, the study was terminated by the sponsor due to PK variability.
Conditions
- Solid Tumors and Hematologic Malignancy
Interventions
- DRUG: INCB054329 Monotherapy
Sponsor
Incyte Corporation